← Back to headlines
Wells Fargo upgrades Ultragenyx Pharma stock on clinical data
Wells Fargo analysts raised their price target for Ultragenyx Pharmaceutical following positive Phase 3 trial results, citing improved therapeutic outcomes and commercial potential.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Homeland Security Secretary’s Plane Makes Emergency Landing After Engine Failure
31m ago
Berkshire Hathaway Signals Long-Term Commitment to Japanese Trading Houses
40m ago
South Korean Utility Proposes $15 Billion Upfront Power Payment From Samsung
1h ago
Chevron Confirms Expansion of Oil Operations in Venezuela
1h ago